financetom
Business
financetom
/
Business
/
Paramount Analyst On Risk-Reward After Skydance Merger: 'We Think Shares Are Worth A Shot At The Current Price'
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Paramount Analyst On Risk-Reward After Skydance Merger: 'We Think Shares Are Worth A Shot At The Current Price'
Jul 9, 2024 1:29 PM

A leading analyst sizes up the impact on the future growth of Paramount Global ( PARAA ) after the media company announced a merger with Skydance.

The Paramount Analyst: Benchmark analyst Daniel Kurnos has a Buy rating on Paramount and a $19 price target.

The Analyst Takeaways: The merger between Paramount and Skydance ends months of speculation of who would acquire the media company, Kurnos said in a new investor note.

"We finally have an official announcement on the board for Paramount that should, hopefully, bring about a close to this real-life drama," Kurnos said.

The analyst said that a 45-day go-shop window could see other bidders on Paramount.

"This is probably the best strategic deal Paramount is likely to be offered that comes closest to satisfying all parties, at least in part."

Kurnos said there is upside ahead for Paramount based on estimates from Skydance that are "achievable" and the analyst's own estimates.

"Understanding that the road will likely be very uneven, we think shares are worth a shot at the current price."

New management is more open to monetizing content on third-party platforms and being part of streaming partnerships and joint ventures, the analyst added.

"It is difficult to tell if management is being conservative, assuming a more focused, paired down strategy, or how much is expected from asset sales."

Read Also: Paramount Analysts Size Up Merger: Skydance Aims For Earnings, ‘Not A Breakup,’ Redstone Says Content Is King

Kurnos noted that the decline in Paramount shares following the merger indicates investor dissatisfaction with the current deal, as well as skepticism about the prospects of a more favorable one emerging. He also pointed out that issuing equity to Skydance dilutes existing shareholders’ stakes.

The analyst estimates that a $14 bear case is a "reasonable valuation shorter-term" and places an $8 worst-case scenario price target on the stock. The analyst's bull case and "pie-in-the-sky outcome" is $26 per share for Paramount in the future.

Kurnos said estimates from the Skydance team could be conservative when it comes to synergies and growth.

"We cannot imagine Skydance setting a high bar out of the gate."

A blended mix of outcomes sees the analyst highlight the risk reward potential of the stock, with 15% risk to the downside and 30% upside to the Skydance forecast.

"We think the range of outcomes looks something like this, with a bit more weighting towards our upside scenario than the bear-case view given our fundamental work."

PARA Price Action: Paramount shares were up 3.1% to $11.53 on Tuesday, versus a 52-week trading range of $9.54 to $17.50. Paramount stock is down 24% year-to-date in 2024.

Read Next:

Paramount Technical Signals Point To Potential Upside On Heels Of Skydance Deal

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Copyright 2023-2026 - www.financetom.com All Rights Reserved